title: Inhibition of human pancreatic tumor growth by cytokine-induced killer cells in nude mouse xenograft model.
abstract: Pancreatic cancer is the fourth commonest cause of cancer-related deaths in the world. However, no adequate therapy for pancreatic cancer has yet been found. In this study, the antitumor activity of cytokine-induced killer (CIK) cells against the human pancreatic cancer was evaluated in vitro and in vivo. Human peripheral blood mononuclear cells were cultured with IL-2-containing medium in anti-CD3 for 14 days. The resulting populations of CIK cells comprised 94% CD3(+), 4% CD3(-)CD56(+), 41% CD3(+)CD56(+), 11% CD4(+), and 73% CD8(+). This heterogeneous cell population was called cytokine-induced killer (CIK) cells. At an effector-target cell ratio of 100:1, CIK cells destroyed 51% of AsPC-1 human pancreatic cancer cells, as measured by the (51)Cr-release assay. In addition, CIK cells at doses of 3 and 10 million cells per mouse inhibited 42% and 70% of AsPC-1 tumor growth in nude mouse xenograft assays, respectively. This study suggests that CIK cells may be used as an adoptive immunotherapy for pancreatic cancer patients.
authors: College of Pharmacy, Chungbuk National University, Cheongju 361-763, Korea.
authors: Ji Sung
authors: JS
authors: Kim
authors: Yun Soo
authors: YS
authors: Park
authors: Ju Young
authors: JY
authors: Kim
authors: Yong Guk
authors: YG
authors: Kim
authors: Yeon Jin
authors: YJ
authors: Kim
authors: Hong Kyung
authors: HK
authors: Lee
authors: Hyung Sook
authors: HS
authors: Kim
authors: Jin Tae
authors: JT
authors: Hong
authors: Youngsoo
authors: Y
authors: Kim
authors: Sang-Bae
authors: SB
authors: Han
keywords: Adoptive immunotherapy; Cytokine-induced killer cells; Pancreatic cancer
references: Int J Cancer. 2011 Oct 15;129(8):1990-2001
references: 21154809
references: Blood. 2011 Sep 22;118(12):3301-10
references: 21821703
references: HPB (Oxford). 2008;10(1):58-62
references: 18695761
references: Exp Hematol. 2009 May;37(5):616-628.e2
references: 19375652
references: Int Immunopharmacol. 2007 Dec 15;7(13):1802-7
references: 17996691
references: N Engl J Med. 2004 Mar 18;350(12):1200-10
references: 15028824
references: Arch Pharm Res. 2009 May;32(5):781-7
references: 19471894
references: Lancet. 2000 Sep 2;356(9232):802-7
references: 11022927
references: J Exp Med. 1991 Jul 1;174(1):139-49
references: 1711560
references: Int Immunopharmacol. 2009 Mar;9(3):375-80
references: 19105981
references: Immunopharmacology. 1999 Feb;41(2):157-64
references: 10102797
references: Exp Hematol. 1993 Dec;21(13):1673-9
references: 7694868
references: J Clin Oncol. 1997 Jun;15(6):2403-13
references: 9196156
references: Clin Dev Immunol. 2011;2011:267539
references: 21922022
references: Cancer Res. 2007 Mar 1;67(5):2290-7
references: 17332360
references: Science. 2006 Mar 24;311(5768):1780-4
references: 16556847
references: Immunol Res. 2006;36(1-3):137-46
references: 17337774
references: Clin Cancer Res. 2006 Jan 15;12(2):569-76
references: 16428502
references: Cancer Res. 2006 Jul 1;66(13):6826-33
references: 16818660
references: Ai Zheng. 2006 Nov;25(11):1329-33
references: 17094896
references: Int J Cancer. 2006 Sep 15;119(6):1377-82
references: 16642465
references: Int Immunopharmacol. 2007 Jan;7(1):78-87
references: 17161820
references: Cancer Biother Radiopharm. 2005 Apr;20(2):173-80
references: 15869451
references: J Immunol. 1994 Aug 15;153(4):1687-96
references: 7519209
references: Arch Pharm Res. 2007 Nov;30(11):1464-70
references: 18087816
references: Blood. 2004 Apr 15;103(8):3065-72
references: 15070686
references: Biol Blood Marrow Transplant. 2001;7(4):216-22
references: 11349808
references: CA Cancer J Clin. 2010 Sep-Oct;60(5):277-300
references: 20610543
references: Anticancer Res. 2006 Sep-Oct;26(5A):3327-32
references: 17094448
references: Int Immunopharmacol. 2007 Dec 15;7(13):1793-801
references: 17996690